Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A, Bovée JVMG.

Oncogenesis. 2018 Sep 21;7(9):74. doi: 10.1038/s41389-018-0084-0.

2.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

3.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

4.

Distinct Patterns of Somatic Mosaicism in the APC Gene in Neoplasms From Patients With Unexplained Adenomatous Polyposis.

Jansen AM, Crobach S, Geurts-Giele WR, van den Akker BE, Garcia MV, Ruano D, Nielsen M, Tops CM, Wijnen JT, Hes FJ, van Wezel T, Dinjens WN, Morreau H.

Gastroenterology. 2017 Feb;152(3):546-549.e3. doi: 10.1053/j.gastro.2016.10.040. Epub 2016 Nov 2.

PMID:
27816598
5.

Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.

Jansen AM, Geilenkirchen MA, van Wezel T, Jagmohan-Changur SC, Ruano D, van der Klift HM, van den Akker BE, Laros JF, van Galen M, Wagner A, Letteboer TG, Gómez-García EB, Tops CM, Vasen HF, Devilee P, Hes FJ, Morreau H, Wijnen JT.

PLoS One. 2016 Jun 14;11(6):e0157381. doi: 10.1371/journal.pone.0157381. eCollection 2016.

6.

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.

de Graaff MA, de Rooij MA, van den Akker BE, Gelderblom H, Chibon F, Coindre JM, Marino-Enriquez A, Fletcher JA, Cleton-Jansen AM, Bovée JV.

Br J Cancer. 2016 May 24;114(11):1219-26. doi: 10.1038/bjc.2016.117. Epub 2016 May 3.

7.

Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.

Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG, Gómez-García EB, Devilee P, Wijnen JT, Hes FJ, Morreau H.

Eur J Hum Genet. 2016 Jul;24(7):1089-92. doi: 10.1038/ejhg.2015.252. Epub 2015 Dec 9.

8.

Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.

Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovée JV, Gomes CM, Cleton-Jansen AM.

J Cell Physiol. 2016 Apr;231(4):876-86. doi: 10.1002/jcp.25179. Epub 2015 Sep 9.

PMID:
26332365
9.

Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2.

de Miranda NF, van Dinther M, van den Akker BE, van Wezel T, ten Dijke P, Morreau H.

Gastroenterology. 2015 Jun;148(7):1427-37.e8. doi: 10.1053/j.gastro.2015.02.052. Epub 2015 Feb 28.

PMID:
25736321
10.

Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.

Kuijjer ML, van den Akker BE, Hilhorst R, Mommersteeg M, Buddingh EP, Serra M, Bürger H, Hogendoorn PC, Cleton-Jansen AM.

BMC Med Genomics. 2014 Jan 21;7:4. doi: 10.1186/1755-8794-7-4.

11.

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

12.

Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.

van Oosterwijk JG, Meijer D, van Ruler MA, van den Akker BE, Oosting J, Krenács T, Picci P, Flanagan AM, Liegl-Atzwanger B, Leithner A, Athanasou N, Daugaard S, Hogendoorn PC, Bovée JV.

Am J Pathol. 2013 Apr;182(4):1347-56. doi: 10.1016/j.ajpath.2012.12.036. Epub 2013 Feb 15.

PMID:
23415961
13.

Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.

Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, Bovée JV.

Genes Chromosomes Cancer. 2012 Oct;51(10):899-909. doi: 10.1002/gcc.21974. Epub 2012 Jun 4.

PMID:
22674453
14.

COX-2 expression in chondrosarcoma: a role for celecoxib treatment?

Schrage YM, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker BE, Taminiau AH, Kalinski T, Llombart-Bosch A, Bovée JV.

Eur J Cancer. 2010 Feb;46(3):616-24. doi: 10.1016/j.ejca.2009.11.002. Epub 2009 Dec 11.

PMID:
20004565
15.

Prevalence of human papillomavirus in Indonesia: a population-based study in three regions.

Vet JN, de Boer MA, van den Akker BE, Siregar B, Lisnawati, Budiningsih S, Tyasmorowati D, Moestikaningsih, Cornain S, Peters AA, Fleuren GJ.

Br J Cancer. 2008 Jul 8;99(1):214-8.

16.

Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.

de Boer MA, Jordanova ES, van Poelgeest MI, van den Akker BE, van der Burg SH, Kenter GG, Fleuren GJ.

Int J Cancer. 2007 Dec 15;121(12):2711-5.

17.

Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia.

de Boer MA, Vet JN, Aziz MF, Cornain S, Purwoto G, van den Akker BE, Dijkman A, Peters AA, Fleuren GJ.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1809-14.

PMID:
17009976

Supplemental Content

Loading ...
Support Center